Regulatory 9 May 2024 FDA green and red lights: April 2024 A tumour-agnostic label for Enhertu leads April’s US oncology approvals. Read more
Data insights Regulatory 15 February 2024 Make or break time for Iovance Lifileucel heads up the list of upcoming US FDA catalysts. Read more